Treatment strategies for lung cancer have changed dramatically with the recent discovery that a proportion of non-small cell lung cancers (NSCLC) harbor activating mutations in the epidermal growth factor receptor (EGFR) gene [3,4], and that the mutated EGFR proteins are particularly susceptible to inhibition by small-molecule tyrosine kinase inhibitors (TKIs) Gefitinib and Erlotinib [5-9]. Here, EGFR is linked to lung carcinoma.